Program
pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0
Its studies are mostly in Carcinoma, Merkel Cell · Neoplasm Metastasis · Carcinoma, Basal Cell · Melanoma, led by TuHURA Biosciences.
Drug pagePDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TuHURA Biosciences | 52 open or running | phase 3since Apr 14, 2025 | Aug 23, 2018 | Mar 31, 2027phase 3 · NCT06947928 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 23, 2018First study: early phase 1 study in MelanomaFirst studyNCT03655756 · 7 enrolled · United States
- Nov 7, 2019Phase 1 study in Carcinoma, Merkel CellNCT04160065 · 23 enrolled · United States
- Jun 2, 2021Phase 1 study in Carcinoma, Basal CellNCT04925713 · 5 enrolled · United States
- Apr 3, 2025Phase 1 study in Neoplasm MetastasisNCT06940440 · 9 planned · United States
- Apr 14, 2025Phase 3 study in Carcinoma, Merkel CellNCT06947928 · 118 planned · United States
Ahead
- Mar 31, 2027Primary completion: phase 3 study in Carcinoma, Merkel CellNCT06947928
- Apr 2027Primary completion: phase 1 study in Neoplasm MetastasisNCT06940440
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06947928Carcinoma, Merkel Cell · United States | 3 | Recruiting | Mar 31, 2027 | 118 |
| NCT06940440Neoplasm Metastasis · United States | 1 | Recruiting | Apr 2027 | 9 |
| NCT04925713Carcinoma, Basal Cell · United States | 1 | Completed | Oct 7, 2021 | 5 |
| NCT04160065Carcinoma, Merkel Cell · United States | 1 | Completed | Oct 19, 2023 | 23 |
| NCT03655756Melanoma · United States | Early 1 | Completed | Jul 10, 2020 | 7 |
How it is read
Names in the registry
- “IFx-Hu2.0”, 5 entries
Conditions, from the studies’ own filings
- Carcinoma, Merkel Cell, 2 studies
- Neoplasm Metastasis, 1 study
- Carcinoma, Basal Cell, 1 study
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.